These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt, with results Terminated 2015-000399-81 AN INTERVENTIONAL, SINGLE ARM, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF APZ2 ON WOUND HEALING OF CHRONIC VENOUS ULCER (CVU) 2020-03-27 not-yet-due
Exempt, with results 2017-000233-31 An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of chronic venous ulcer (CVU). 2020-06-25 not-yet-due
Exempt, with results 2017-000234-57 An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU). 2020-06-29 not-yet-due
Exempt, with results Terminated 2017-000235-14 A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, INTERVENTIONAL, MULTICENTER, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ALLO-APZ2-PAOD FOR THE TREATMENT OF PERIPHERAL ARTERIA... 2020-05-15 not-yet-due
Exempt Terminated 2017-001790-16 AN INTERVENTIONAL, OPEN-LABEL, MULTICENTER PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF ASCENDING DOSES OF ALLOGENEIC ABCB5-POSITIVE LIMBAL STEM CELLS (LSC2) FOR THE TREATMENT ... 2022-06-07 not-yet-due
Exempt, with results 2018-001009-98 An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) 2021-11-26 not-yet-due
Exempt, with results Terminated 2018-001240-61 An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF) 2021-03-26 not-yet-due
Other 2020-004960-24 A randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chroni... not-yet-due